Cutaneous Squamous Cell Carcinoma

Questions discussed in this category

How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?

Consider a mass ~3 cm in width with 1 cm thickness located on the helix, with apparent cartilage invasion. Would you treat with electrons or photons,...

4 Answers available

Would you consider neoadjuvant immunotherapy prior to radiation for a locally advanced skin squamous cell carcinoma?

If so, would you modify your radiation dose/field size to account for immunotherapy response? After how many cycles?

2 Answers available

How would a low tumor mutational burden (<10) influence your decision to offer neoadjuvant immunotherapy for cutaneous squamous cell carcinoma?

3 Answers available

How would you approach treatment failures with squamous cell carcinoma-keratoacanthoma-type lesions that did not respond to a standard SRT regimen after many sessions?

Have you encountered this scenario?

3 Answers available

Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?

Are there other settings where MRI is used for nerve assessment and radiation planning such as for certain definitive RT cases?

5 Answers available

Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?

6 Answers available

How would you manage a scalp squamous cell carcinoma s/p Mohs with high risk features who underwent placental grafting to expedite the healing process?

When is it safe to deliver adjuvant radiation?

1 Answer available

How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?

Patient has had previous failure of methotrexate. Would you switch to alternative (TNFi or Rituximab) or continue abatacept with regular dermatology...

2 Answers available

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

4 Answers available

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

3 Answers available

What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?

3 Answers available